Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation

被引：31
作者：
Soni, Sandeep [1 ]
Skeens, Micah [1 ]
Termuhlen, Amanda M. [1 ]
Bajwa, Rajinder P. S. [1 ]
Gross, Thomas G. [1 ]
Pai, Vinita [1 ,2 ]
机构：
[1] Nationwide Childrens Hosp, Div Pediat Hematol Oncol & BMT, Columbus, OH 43205 USA
[2] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA
来源：
PEDIATRIC BLOOD & CANCER | 2012年 / 59卷 / 04期
关键词：
BMT; busulfan; levetiracetam; seizures; HIGH-DOSE BUSULFAN; ACUTE-LEUKEMIA PATIENTS; MARROW TRANSPLANTATION; DRUG-INTERACTIONS; PHARMACOKINETICS; CYCLOPHOSPHAMIDE; LORAZEPAM;
D O I：
10.1002/pbc.24126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Anti-seizure prophylaxis is routinely utilized during busulfan administration for HSCT. We evaluated the feasibility and efficacy of levetiracetam in children undergoing HSCT. A total of 28 children and young adults received levetiracetam during HSCT and the outcomes and costs were compared to a historical, but similar cohort of 25 patients who had received fosphenytoin. Levetiracetam was well tolerated and was efficacious in preventing seizures. Cost of drug, administration, and monitoring were also similar among the two groups. Due to non-induction of the hepatic cytochrome P450 enzymes, levetiracetam may lead to better dose assurance of busulfan in targeted dose regimens for HSCT. Pediatr Blood Cancer 2012;59:762764. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码：762 / 764
页数：3
相关论文
共 50 条
  • [31] Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting
    Ruiz-Argueelles, Guillermo J.
    Gomez-Almaguer, David
    Steensma, David P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (09) : 941 - 941
  • [32] Predicting busulfan exposure in patients undergoing hematopoietic stem cell transplantation using machine learning techniques
    Li, Dandan
    Zhao, Jingtong
    Xu, Baohua
    Zheng, You
    Liu, Maobai
    Huang, Huiping
    Han, Song
    Wu, Xuemei
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (08) : 751 - 761
  • [33] Pharmacokinetics and tolerability of intravenous busulfan in hematopoietic stem cell transplantation
    Cho, Yo-Han
    Lim, Hyun-Ae
    Lee, Mark Hong
    Kim, Inho
    Lee, Jong Seok
    Park, Seong yang
    Kim, Byoung Kook
    Yoon, Sung-Soo
    CLINICAL TRANSPLANTATION, 2007, 21 (03) : 417 - 422
  • [34] Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation
    McCune, JS
    Gooley, T
    Gibbs, JP
    Sanders, JE
    Petersdorf, EW
    Appelbaum, FR
    Anasetti, C
    Risler, L
    Sultan, D
    Slattery, JT
    BONE MARROW TRANSPLANTATION, 2002, 30 (03) : 167 - 173
  • [35] Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation
    JS McCune
    T Gooley
    JP Gibbs
    JE Sanders
    EW Petersdorf
    FR Appelbaum
    C Anasetti
    L Risler
    D Sultan
    JT Slattery
    Bone Marrow Transplantation, 2002, 30 : 167 - 173
  • [36] Pharmacokinetic Behavior and Appraisal of Intravenous Busulfan Dosing in Infants and Older Children: The Results of a Population Pharmacokinetic Study From a Large Pediatric Cohort Undergoing Hematopoietic Stem-Cell Transplantation
    Paci, Angelo
    Vassal, Gilles
    Moshous, Despina
    Dalle, Jean-Hugues
    Bleyzac, Nathalie
    Neven, Benedicte
    Galambrun, Claire
    Kemmel, Veronique
    Abdi, Zeinab D.
    Broutin, Sophie
    Petain, Aurelie
    Laurent Nguyen
    THERAPEUTIC DRUG MONITORING, 2012, 34 (02) : 198 - 208
  • [37] GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study
    Ansari, Marc
    Curtis, Patricia Huezo-Diaz
    Uppugunduri, Chakradhara Rao S.
    Rezgui, Mohammed Aziz
    Nava, Tiago
    Mlakar, Vid
    Lesne, Laurence
    Theoret, Yves
    Chalandon, Yves
    Dupuis, Lee L.
    Schechter, Tao
    Bartelink, Imke H.
    Boelens, Jaap J.
    Bredius, Robbert
    Dalle, Jean-Hugues
    Azarnoush, Saba
    Sedlacek, Petr
    Lewis, Victor
    Champagne, Martin
    Peters, Christina
    Bittencourt, Henrique
    Krajinovic, Maja
    ONCOTARGET, 2017, 8 (53) : 90852 - 90867
  • [38] IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant:: Limited sampling strategies
    Dupuis, L. Lee
    Sibbald, Cathryn
    Schechter, Tal
    Ansari, Marc
    Gassas, Adam
    Theoret, Yves
    Kassir, Nastya
    Champagne, Martin A.
    Doyle, John
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (05) : 576 - 582
  • [39] Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children
    Huezo-Diaz, Patricia
    Uppugunduri, Chakradhara Rao S.
    Tyagi, Anuj Kumar
    Krajinovic, Maja
    Ansari, Marc
    CURRENT DRUG METABOLISM, 2014, 15 (03) : 251 - 264
  • [40] Use of an Oral Busulfan Test Dose in Patients Undergoing Hematopoietic Stem Cell Transplantation Treated With or Without Fludarabine
    de Castro, Francine Attie
    Simoes, Belinda Pinto
    Pardo Campos Godoy, Ana Leonor
    Bertagnoli Trigo, Fernanda Manuela
    Coelho, Eduardo Barbosa
    Lanchote, Vera Lucia
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (12) : 1555 - 1562
12345